Back to GRFSView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
View Full LandscapeDrug Information
Target Indication
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Clinical Trial
NCT00220740Last updated: 2/13/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
Albutein 20%Phase 3
Decompensated Cirrhosis and Ascites
FS GrifolsPhase 3
Target Bleeding Site During Peripheral Vascular Surgery
Liquid Alpha₁-PIPhase 3
Alpha₁-Antitrypsin Deficiency
Alpha-1 MPPhase 3
Alpha 1-Antitrypsin Deficiency
alpha-1 proteinase inhibitor (human)Phase 3
Alpha 1-Antitrypsin Deficiency
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts